Townsend Richard Nolan 4
4 · Lexeo Therapeutics, Inc. · Filed Jan 10, 2025
Insider Transaction Report
Form 4
Townsend Richard Nolan
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-07+207,500→ 207,500 totalExercise: $7.33Exp: 2035-01-06→ Common Stock (207,500 underlying) - Award
Common Stock
2025-01-07+103,750→ 224,445 total
Footnotes (3)
- [F1]The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Includes 147,500 RSUs.
- [F3]25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.